参考文献/References:
[1]Sacco RL,Roth GA,Reddy KS,et al. The heart of 25 by 25:achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke:a modeling study from the American heart association and world heart federation[J]. Circulation,2016,133(23):e674-e690.
[2]Rosenblit PD. Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition[J]. Curr Diab Rep,2019,19(8):61.
[3]Choi S. The potential role of biomarkers associated with ASCVD risk:risk-enhancing biomarkers[J]. J Lipid Atheroscler,2019,8(2):173-182.
[4]Zhao D,Liu J,Wang M,et al. Epidemiology of cardiovascular disease in China:current features and implications[J]. Nat Rev Cardiol,2019,16(4):203-212.
[5]Mancusi C,de Simone G,Best LG,et al. Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the Strong Heart Study cohort[J]. Cardiovasc Diabetol,2019,18(1):56.
[6]Hill MA,Yang Y,Zhang L,et al. Insulin resistance,cardiovascular stiffening and cardiovascular disease[J]. Metabolism,2021,119:154766.
[7]Minh HV,Tien HA,Sinh CT,et al. Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension[J]. J Clin Hypertens (Greenwich),2021,23(3):529-537.
[8]Placzkowska S,Pawlik-Sobecka L,Kokot I,et al. Indirect insulin resistance detection:current clinical trends and laboratory limitations[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2019,163(3):187-199.
[9]Park K,Ahn CW,Lee SB,et al. Elevated TyG index predicts progression of coronary artery calcification[J]. Diabetes Care,2019,42(8):1569-1573.
[10]Won KB,Kim YS,Lee BK,et al. The relationship of insulin resistance estimated by triglyceride glucose index and coronary plaque characteristics[J]. Medicine (Baltimore),2018,97(21):e10726.
[11]Thai PV,Tien HA,Van Minh H,et al. Triglyceride glucose index for the detection of asymptomatic coronary artery stenosis in patients with type 2 diabetes[J]. Cardiovasc Diabetol,2020,19(1):137.
[12]Cho YR,Ann SH,Won KB,et al. Association between insulin resistance,hyperglycemia,and coronary artery disease according to the presence of diabetes[J]. Sci Rep,2019,9(1):6129.
[13]Wang M,Mei L,Jin A,et al. Association between triglyceride glucose index and atherosclerotic plaques and Burden:findings from a community-based study[J]. Cardiovasc Diabetol,2022,21(1):204.
[14]Lee SB,Ahn CW,Lee BK,et al. Association between triglyceride glucose index and arterial stiffness in Korean adults[J]. Cardiovasc Diabetol,2018,17(1):41.
[15]Kim MK,Ahn CW,Kang S,et al. Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults[J]. Cardiovasc Diabetol,2017,16(1):108.
[16]Zhao Q,Zhang TY,Cheng YJ,et al. Triglyceride-glucose index as a surrogate marker of insulin resistance for predicting cardiovascular outcomes in nondiabetic patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention[J]. J Atheroscler Thromb,2021,28(11):1175-1194.
[17]Zhao Q,Zhang TY,Cheng YJ,et al. Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome:results from an observational cohort study in China[J]. Cardiovasc Diabetol,2020,19(1):108.
[18]Mao Q,Zhou D,Li Y,et al. The triglyceride-glucose index predicts coronary artery disease severity and cardiovascular outcomes in patients with non-ST-segment elevation acute coronary syndrome[J]. Dis Markers,2019,2019:6891537.
[19]Vogel B,Claessen BE,Arnold SV,et al. ST-segment elevation myocardial infarction[J]. Nat Rev Dis Primers,2019,5(1):39.
[20]Karadeniz F?,Sancaktepe EA,Karadeniz Y. High triglyceride-glucose index is associated with poor prognosis in patients with acute coronary syndrome in long-term follow-up[J]. Angiology,2023,74(2):139-148.
[21]Ybarra LF,Rinfret S,Brilakis ES,et al. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies:CTO-ARC consensus recommendations[J]. Circulation,2021,143(5):479-500.
[22]Vanhaverbeke M,Eertmans W,Holvoet W,et al. Contemporary strategies and outcomes of dedicated chronic total occlusion percutaneous coronary intervention programs:a prospective multicentre registry[J]. J Interv Cardiol,2021,2021:8042633.
[23]Wu EB,Tsuchikane E,Ge L,et al. Retrograde versus antegrade approach for coronary chronic total occlusion in an algorithm-driven contemporary Asia-pacific multicentre registry:comparison of outcomes[J]. Heart Lung Circ,2020,29(6):894-903.
[24]Hirai T,Grantham JA,Sapontis J,et al. Quality of life changes after chronic total occlusion angioplasty in patients with baseline refractory angina[J]. Circ Cardiovasc Interv,2019,12(3):e007558.
[25]Park TK,Lee SH,Choi KH,et al. Late survival benefit of percutaneous coronary intervention compared with medical therapy in patients with coronary chronic total occlusion:a 10-year follow-up study[J]. J Am Heart Assoc,2021,10(6):e019022.
[26]Li Y,He S,Wu Z,et al. The predictive value of the triglyceride-glucose index for cardiovascular events in patients with coronary chronic total occlusion[J]. Cardiovasc Diabetol,2022,21(1):149.
[27]Gao A,Liu J,Hu C,et al. Association between the triglyceride glucose index and coronary collateralization in coronary artery disease patients with chronic total occlusion lesions[J]. Lipids Health Dis,2021,20(1):140.
[28]Wang J,Huang X,Fu C,et al. Association between triglyceride glucose index,coronary artery calcification and multivessel coronary disease in Chinese patients with acute coronary syndrome[J]. Cardiovasc Diabetol,2022,21(1):187.
[29]梁艳胜. 冠状动脉钙化积分和甘油三酯葡萄糖乘积指数与ACS患者冠脉多支病变的关系[J].山东大学,2021,2021.000936.
[30]Byrne R,Joner M,Kastrati A. Stent thrombosis and restenosis:what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014[J]. Eur Heart J,2015,36(47):3320-3331.
[31]Liu S,Yang Y,Jiang S,et al. Understanding the role of non-coding RNA (ncRNA) in stent restenosis[J]. Atherosclerosis,2018,272:153-161.
[32]Zhu Y,Liu K,Chen M,et al. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents[J]. Cardiovasc Diabetol,2021,20(1):137.
[33]陈玲玲,李波.甘油三酯葡萄糖指数与冠心病患者经皮冠状动脉介入术后发生支架内再狭窄的关联性研究[J].中国临床新医学,2022,15(07):631-635.
[34]Paquin A,Poirier P,Beaudoin J,et al. Secondary prevention after CABG:do new agents change the paradigm?[J]. Curr Opin Cardiol,2020,35(6):664-672.
[35]Zhang H,Chong H,Li Z,et al. Triglyceride-glucose index in the prediction of major adverse cardiovascular events in patients with type 2 diabetes mellitus after coronary artery bypass surgery:a retrospective cohort study[J]. Front Endocrinol (Lausanne),2022,13:1015747.
[36]Chen L,Ding XH,Fan KJ,et al. Association between triglyceride-glucose index and 2-year adverse cardiovascular and cerebrovascular events in patients with type 2 diabetes mellitus who underwent off-pump coronary artery bypass grafting[J]. Diabetes Metab Syndr Obes,2022,15:439-450.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(9):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[3]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[4]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[5]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(9):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[6]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(9):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[7]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(9):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[8]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(9):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
[9].胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展[J].心血管病学进展,2022,(7):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
ZHU Jie,GAO Fen,XUE Shuanqin,et al.Treatment of Atherosclerotic Cardiovascular Diseases with Cholesteryl Ester Transfer Protein Inhibitor[J].Advances in Cardiovascular Diseases,2022,(9):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[10]欧阳运峰 李皇庆 李璐 阳军.脂蛋白a：动脉粥样硬化性心血管疾病防治新靶点[J].心血管病学进展,2022,(8):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
OUYANG Yunfeng,LI Huangqing,LI Lu,et al.Lipoprotein A:a New Target for Prevention and Treatment of Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(9):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]